|
Real-time Estimate
Cboe Europe
08:35:13 2026-09-16 am EDT
|
5-day change | 1st Jan Change | ||
| 12,205.00 GBX | +0.73% |
|
+4.82% | -11.44% |
| 04:47am | Daiichi and AstraZeneca cancer drugs secure further approvals in Japan | AN |
| 04:32am | AstraZeneca PLC : Gets a Buy rating from UBS | ZD |
| Market Cap | 253B 220B 208B 188B 353B 24,310B 355B 2,477B 953B 12,326B 952B 931B 39,310B | P/E 2026 * |
20.9x | P/E 2027 * | 18.2x |
|---|---|---|---|---|---|
| Enterprise Value | 273B 236B 224B 202B 380B 26,186B 383B 2,668B 1,027B 13,278B 1,025B 1,003B 42,345B | EV / Sales 2026 * |
4.31x | EV / Sales 2027 * | 3.97x |
| Free-Float |
96.63% | Yield 2026 * |
2.04% | Yield 2027 * | 2.18% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AZN | Delayed | |
NYSE
| AZN | End-of-day quote | |
|
Nasdaq Stockholm
| AZN | Delayed | |
|
CBOE
| AZN | Real-time | |
|
CBOE
| AZNs | Real-time | |
|
CBOE
| AZN | Real-time | |
|
Tradegate
| ZEG | Real-time | |
|
Börse Stuttgart
| ZEG | Delayed | |
|
Boerse Muenchen
| ZEG | Real-time | |
|
Deutsche Boerse AG
| ZEG | Delayed | |
|
CBOE
| AZN | Real-time | |
|
Mexican S.E.
| AZN1 N | End-of-day quote | |
|
Berne S.E.
| 000982352 | End-of-day quote |
Last Transcript: AstraZeneca PLC
| 1 day | +0.72% | ||
| 1 week | +4.82% | ||
| Current month | +2.02% | ||
| 1 month | +5.64% | ||
| 3 months | -8.07% | ||
| 6 months | -14.98% | ||
| Current year | -11.44% |
| 1 week | 11,552 |  | 12,244 |
| 1 month | 11,488 | | 12,476 |
| Current year | 10,524 | | 15,732 |
| 1 year | 10,524 | | 15,732 |
| 3 years | 9,461 | | 15,732 |
| 5 years | 8,029 | | 15,732 |
| 10 years | 3,996 | | 15,732 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 2021-07-31 |
Jeffrey Pott
CMP | Compliance Officer | - | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 65 | 2017-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/8/26 | Free | See Remarks | 1 | 0.0000% | - | |
| 8/17/26 | Exercice | Chief Financial Officer | 11,133 | 0.0007% | ||
| 8/6/26 | Free | SVP, Group Controller | 2 | 0.0000% | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.73% | +4.82% | +7.63% | +13.83% | 253B | |
| -0.19% | +1.09% | +51.85% | +97.36% | 1,013B | |
| +0.33% | -0.71% | +50.62% | +65.50% | 644B | |
| +0.49% | +5.73% | +20.88% | +72.92% | 465B | |
| +0.49% | +4.29% | +40.33% | +40.57% | 352B | |
| +1.08% | +3.03% | +18.74% | +25.02% | 264B | |
| -1.53% | -4.46% | +36.90% | +44.08% | 203B | |
| +0.24% | -3.96% | -22.74% | -57.34% | 188B | |
| -0.08% | -0.23% | +30.00% | +93.34% | 181B | |
| -0.61% | -0.86% | +14.94% | -19.14% | 157B | |
| Average | +0.38% | -1.06% | +24.91% | +37.61% | 372.07B | |
| Weighted average by Cap. | +0.39% | -0.02% | +34.10% | +56.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.28B 54.81B 51.83B 46.92B 88.06B 6,070B 88.73B 618B 238B 3,078B 238B 232B 9,815B | 66.88B 57.93B 54.78B 49.6B 93.08B 6,416B 93.78B 654B 252B 3,253B 251B 246B 10,375B |
| Net income | 12.07B 10.46B 9.89B 8.95B 16.8B 1,158B 16.93B 118B 45.39B 587B 45.34B 44.34B 1,872B | 13.8B 11.96B 11.31B 10.24B 19.21B 1,324B 19.36B 135B 51.91B 671B 51.85B 50.7B 2,141B |
| Net Debt | 19.56B 16.94B 16.02B 14.51B 27.22B 1,876B 27.43B 191B 73.56B 951B 73.48B 71.85B 3,034B | 11.78B 10.2B 9.65B 8.74B 16.4B 1,130B 16.52B 115B 44.3B 573B 44.25B 43.27B 1,827B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-16 | GBX 12,213.04 | +0.80% | 377,384 |
| 26-09-15 | GBX 12,116.00 | -0.31% | 3,056,945 |
| 26-09-14 | GBX 12,154.00 | +3.81% | 6,470,195 |
| 26-09-11 | GBX 11,708.00 | -0.43% | 1,474,761 |
| 26-09-10 | GBX 11,758.00 | +0.93% | 2,070,438 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
